Accuray Incorporated develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Company news centers on product and service revenue, installation timing, gross margin factors, and non-GAAP operating measures, as well as updates tied to its CyberKnife and Radixact treatment platforms and the Accuray Stellar configuration.
Recurring developments also include commercial leadership changes, equity inducement awards, and strategic transformation actions involving organizational realignment, cost structure, outsourcing, engineering resources, and sales enablement. Accuray's updates frame the company as a medical technology issuer with capital equipment sales, service revenue, and global commercialization priorities.
Accuray Incorporated (NASDAQ: ARAY) reported strong Q4 FY2024 results with 13.5% revenue growth to $134.3 million and a return to profitability with $3.4 million net income. Key highlights include:
- 7.9% increase in gross orders to $95.5 million
- Record quarterly system shipments, up 24% year-over-year
- Adjusted EBITDA of $10.1 million, nearly double the prior year
- Book-to-bill ratio of 1.2
For full FY2024, revenue was relatively flat at $446.6 million with a net loss of $15.5 million. The company achieved 10% growth in gross orders to $342.1 million for the year. Accuray also announced new product approvals and market expansions, positioning for future growth.
Halifax Health in Florida has become the first in the U.S. to treat cancer patients using the Accuray Radixact® System with VitalHold™ technology. This advanced system, housed at the Cancer Center for Hope – Port Orange, combines ClearRT® helical CT imaging and Synchrony® real-time adaptive delivery technologies to enhance precision in radiation delivery.
The VitalHold feature incorporates a fully integrated and automated surface-guided radiotherapy (SGRT) solution from C-RAD, offering benefits such as highly accurate patient positioning and enabling deep inspiration breath hold (DIBH) treatments. This technology aims to minimize radiation dose to organs at risk and supports tattoo-free positioning for improved patient comfort.
The implementation of this system demonstrates Halifax Health's commitment to providing cutting-edge cancer care to the Volusia County community, potentially improving treatment outcomes and patient quality of life.
Accuray Incorporated (NASDAQ: ARAY) has announced it will report its fourth quarter fiscal 2024 financial results on August 14, 2024. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day. Investors can access the call via phone or a live webcast from the company's website. A replay of the call will be available for one week after the event.
Accuray is a Madison, Wisconsin-based company that specializes in innovative radiation therapy solutions for oncology and neuro-radiosurgery. The company focuses on developing technologies to treat complex cases while simplifying common treatments, aiming to improve patient outcomes and quality of life.
Accuray announced that Heidelberg University Hospital in Germany has opted to replace its existing TomoTherapy System with Accuray's Radixact System. The Radixact System will be outfitted with ClearRT, Synchrony, and VOLO Ultra Optimizer to improve the precision and speed of cancer treatment. This upgrade is intended to enhance the hospital's capacity to treat a wide range of cancer cases more effectively and efficiently. Heidelberg University Hospital, a well-regarded institution globally, is recognized for its excellence in patient care and groundbreaking research and has previously utilized Accuray's technologies to treat up to 100 patients per day.
Accuray (NASDAQ: ARAY) has signed an agreement with TrueNorth Medical Physics to enhance radiation oncology departments' capabilities. TrueNorth will provide third-party support services, including physics, dosimetry, and commissioning for Accuray's TomoTherapy, Radixact, and CyberKnife systems. This partnership aims to assist hospitals with staffing, technology adoption, and the achievement of patient treatment goals. TrueNorth's team brings over 125 combined clinical years of experience to the table, offering services on-site, remotely, or in hybrid formats. This collaboration underscores Accuray's commitment to innovation and improving patient care in radiation therapy.
Accuray announced the approval of its Accuray Precision Treatment Planning System (TPS) by China's National Medical Products Administration (NMPA). This approval allows the system to be used with the CNNC-Accuray joint venture Tomo C radiation therapy system. This combination aims to provide precise radiotherapy treatments, expanding access for cancer patients in China. Suzanne Winter, CEO of Accuray, highlighted the system's benefits in addressing the high incidence of cancer in China. The Accuray Precision TPS facilitates rapid adaptation of treatment plans to changes in tumor characteristics and healthy tissue, enhancing treatment accuracy. The Tomo C platform includes helical imaging and radiation delivery with patented beam-shaping technology, optimizing radiation dose control.
Accuray announced its participation in the Jefferies Global Healthcare Conference 2024. The management team will engage in a fireside chat on June 5, 2024, at 7:30am EDT/4:30am PDT, which will be broadcast live on the company's investor relations website. A replay will be available for 90 days. Accuray focuses on innovating radiation therapy solutions for complex medical cases, aiming to improve patient outcomes globally. The company is headquartered in Madison, Wisconsin, with facilities worldwide.
Accuray Incorporated (NASDAQ: ARAY) reported a decrease in net revenue for the third quarter and nine-months ended March 31, 2024. The GAAP net loss was $6.3 million, with gross orders increasing by 21%. Despite challenges, the company remains confident in its growth strategy and ability to offer value globally.
Summary not available.
Summary not available.